Technology Overview: This NJIT technology is an injectable peptide‑based hydrogel that self‑assembles in situ to form an antibacterial matrix. The hydrogel is composed of engineered peptides that exhibit intrinsic antimicrobial activity while maintaining biocompatibility. Upon injection, the material forms a localized scaffold capable of preventing bacterial colonization and supporting tissue healing. This approach offers a potential alternative to systemic antibiotics, reducing the risk of resistance and systemic side effects.

Industry Pain Point: Post‑surgical and wound infections remain challenging due to antibiotic resistance and limited localized treatment options.

NJIT Solution: This hydrogel provides localized, sustained antibacterial activity via self‑assembling peptide structures.

Key Features & Advantages

• Injectable and self‑assembling
• Intrinsic antibacterial properties
• Localized action with reduced systemic exposure
• Biocompatible and biodegradable

Development Stage: TRL 4–5 – Preclinical laboratory validation completed.

Target Markets

• Surgical and wound care products
• Infection prevention technologies
• Regenerative Medicine Applications

Market Opportunity

• Global wound care market (2026): ~$25B
• CAGR: ~6–7%
• Projected market size (2035): ~$40–45B